Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

584 Articles

Chris Lange | Nov 27, 2019 at 9:00 AM EST

Big Pharma Short Sellers Hike Their Bets

The November 15 short interest data have been compared with the previous figures, and short interest in most of these…

Paul Ausick | Nov 26, 2019 at 12:34 PM EST

Starboard Value Stake Momentarily Shakes Up CVS

A report that activist investor firm Starboard Value had taken a stake in CVS momentarily lifted the drugstore and health…

Chris Lange | Nov 12, 2019 at 8:50 AM EST

Big Pharma Scares Off Short Sellers

The October 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Oct 25, 2019 at 9:59 AM EDT

Short Sellers Can’t Make Up Their Minds on Big Pharma

The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Oct 10, 2019 at 9:40 AM EDT

Big Pharma Sees Rising Tide in Short Interest

The September 30 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Sep 25, 2019 at 9:20 AM EDT

Short Sellers Grow More Selective in Big Pharma

The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Sep 12, 2019 at 8:35 AM EDT

Short Sellers Can’t Make Up Their Minds on Big Pharma

The August 30 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Aug 28, 2019 at 11:20 AM EDT

7 Giant Mergers Transforming the Face of Corporate America

Many mergers have been announced or have closed, but just seven recent and pending deals have transformed how analysts and…

Chris Lange | Aug 27, 2019 at 8:35 AM EDT

Big Pharma Sees a Rising Tide in Short Interest

The August 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 26, 2019 at 3:20 PM EDT

Is Amgen Overpaying for Celgene’s Psoriasis Treatment?

Both Amgen and Celgene shares made a handy gain on Monday after it was announced that the companies had made…

Jon C. Ogg | Aug 12, 2019 at 12:10 PM EDT

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current…

Chris Lange | Aug 12, 2019 at 8:40 AM EDT

Major Pharma Sees Rising Tide in Short Interest

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Aug 7, 2019 at 11:15 AM EDT

Defensive Stocks Standing Strong as Broader Stock Market Indexes Tank

24/7 Wall St. has taken a look at the defensive stocks that are holding up fine on a day that…

Chris Lange | Jul 25, 2019 at 8:35 AM EDT

Short Sellers Up the Ante in Big Pharma

The July 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 11, 2019 at 9:45 AM EDT

Big Pharma Sees Rising Tide in Short Interest

The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected…

1 … 11 12 13 14 15 … 39

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Big Pharma Short Sellers Hike Their Bets

Starboard Value Stake Momentarily Shakes Up CVS

Big Pharma Scares Off Short Sellers

Short Sellers Can’t Make Up Their Minds on Big Pharma

Big Pharma Sees Rising Tide in Short Interest

Short Sellers Grow More Selective in Big Pharma

Short Sellers Can’t Make Up Their Minds on Big Pharma

7 Giant Mergers Transforming the Face of Corporate America

Big Pharma Sees a Rising Tide in Short Interest

Is Amgen Overpaying for Celgene’s Psoriasis Treatment?

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Major Pharma Sees Rising Tide in Short Interest

Defensive Stocks Standing Strong as Broader Stock Market Indexes Tank

Short Sellers Up the Ante in Big Pharma

Big Pharma Sees Rising Tide in Short Interest

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Billionaire Bill Ackman’s Pershing Square Exits Universal Music After Failed Takeover Bids, Stock Slumps 7%

Why Affluent Couples Are Draining the Higher-Earning Spouse's 401(k) First to Avoid the Widow's Tax Penalty

Middle-Class Fortysomethings Have a $427,000 Problem and a Shrinking Window to Fix It

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Big Pharma Short Sellers Hike Their Bets

Starboard Value Stake Momentarily Shakes Up CVS

Big Pharma Scares Off Short Sellers

Short Sellers Can’t Make Up Their Minds on Big Pharma

Big Pharma Sees Rising Tide in Short Interest

Short Sellers Grow More Selective in Big Pharma

Short Sellers Can’t Make Up Their Minds on Big Pharma

7 Giant Mergers Transforming the Face of Corporate America

Big Pharma Sees a Rising Tide in Short Interest

Is Amgen Overpaying for Celgene’s Psoriasis Treatment?

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Major Pharma Sees Rising Tide in Short Interest

Defensive Stocks Standing Strong as Broader Stock Market Indexes Tank

Short Sellers Up the Ante in Big Pharma

Big Pharma Sees Rising Tide in Short Interest

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Billionaire Bill Ackman’s Pershing Square Exits Universal Music After Failed Takeover Bids, Stock Slumps 7%

Featured Reads

Why Affluent Couples Are Draining the Higher-Earning Spouse's 401(k) First to Avoid the Widow's Tax Penalty

Middle-Class Fortysomethings Have a $427,000 Problem and a Shrinking Window to Fix It